Bill giving student loan relief to some veterinarians heads to governor's desk
New Mexico lawmakers push juvenile crime bill before session ends
'We need large animal vets. We are at a huge disadvantage in the state to be able to work our livestock. Any time that we have sick livestock now you have to get a prescription and have to get a vet consultation. Sometimes that could take 2 or 3 days before you can get a vet and by that time it's too late,' said Bronson Corn, New Mexico Cattle Growers' Association President.
The bill now heads to the governor's desk for final action.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
San Francisco Chronicle
2 hours ago
- San Francisco Chronicle
Essential Utilities: Q2 Earnings Snapshot
BRYN MAWR, Pa. (AP) — BRYN MAWR, Pa. (AP) — Essential Utilities, Inc. (WTRG) on Thursday reported second-quarter net income of $107.8 million. On a per-share basis, the Bryn Mawr, Pennsylvania-based company said it had net income of 38 cents. The results beat Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for earnings of 29 cents per share. Essential Utilities expects full-year earnings to be $2.07 to $2.11 per share. _____ This story was generated by Automated Insights ( using data from Zacks Investment Research. Access a Zacks stock report on WTRG at
San Francisco Chronicle
2 hours ago
- San Francisco Chronicle
Hercules Capital: Q2 Earnings Snapshot
SAN MATEO, Calif. (AP) — SAN MATEO, Calif. (AP) — Hercules Capital, Inc. (HTGC) on Thursday reported second-quarter net income of $78.9 million. On a per-share basis, the San Mateo, California-based company said it had net income of 43 cents. Earnings, adjusted for investment costs, were 50 cents per share. The results exceeded Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for earnings of 47 cents per share. The specialty finance company posted revenue of $137.5 million in the period. _____
Business Wire
2 hours ago
- Business Wire
Regenerex Pharma, Inc. Enters Into Licensing Agreement with Holista Colltech Ltd.
LAS VEGAS--(BUSINESS WIRE)--Regenerex Pharma, Inc. (OTC: RGPX), a leading innovator in advanced wound closure systems for chronic wounds, today announced the development of new product formulations designed to accelerate deep tissue regeneration through enhanced scaffolding facilitation and cell proliferation. Building on its patented QBx™ technology, Regenerex will now incorporate ovine nano-collagen into its wound healing protocols. This highly refined biomaterial, due to its ultra-small molecular size, provides an ideal scaffolding matrix to support and accelerate cellular growth, making it especially beneficial in cases requiring deeper tissue regeneration. As part of this strategic advancement, Regenerex has entered into a licensing agreement with Holista Colltech Ltd. ('Holista'), a globally recognized producer of high-purity ovine collagen. Holista's collagen is derived from ethically sourced, disease-free Australian sheep, produced under Australia's rigorous animal health standards. 'Ovine collagen represents a significant step forward in wound care innovation,' said Greg Pilant, CEO of Regenerex Pharma, Inc. 'Unlike traditional mammalian sources such as bovine or porcine collagen, ovine nano-collagen is not only safer—avoiding concerns like mad cow disease—but also more culturally and religiously acceptable in many global markets.' This collaboration allows Regenerex to bring cutting-edge, biologically advanced wound care solutions to both U.S. and international markets. The integration of ovine nano-collagen with Regenerex's QBx™ technology reflects the company's commitment to providing safe, effective, and inclusive wound healing options. About Regenerex Pharma, Inc. The Mission at Regenerex Pharma, Inc. is to provide the next historical solution in human health crises by solving chronic wound closure and reducing amputations resulting from the stalled healing process in chronic wounds. Regenerex's products treat diabetic foot ulcers, venous ulcers, burns, and pressure ulcers, and heal 95% of chronic wounds in 90 days or less using advanced proprietary woundcare products, proven protocols, and proprietary EMR systems. More information about the Company may be found at About Holista Colltech Ltd. Holista Colltech Ltd. is a global leader in the production of high-purity ovine collagen, leveraging Australia's strict biosecurity standards and ethical sourcing practices. The company is committed to sustainable health innovations and the development of premium-grade natural ingredients for medical and consumer applications. More information about the Company may be found at Notice regarding forward-looking statements This press release contains forward-looking statements that may be subject to various risks and uncertainties. Such forward-looking statements are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and may include statements regarding our future financial performance or results of operations, including expected revenue growth. Unless otherwise required by law, we undertake no obligation to publicly update or revise any forward looking statements, whether as a result of new information, future events or otherwise after the date of this press release. Additional information concerning risks and uncertainties that would cause actual results to differ materially from those projected or suggested in the forward-looking statements can be found in the reports that we have filed with the Securities and Exchange Commission.
